HiBGT: High-Performance Bayesian Group Testing for COVID-19

The COVID-19 pandemic has necessitated disease surveillance using group testing. Novel Bayesian methods using lattice models were proposed, which offer substantial improvements in group testing efficiency by precisely quantifying uncertainty in diagnoses, acknowledging varying individual risk and dilution effects, and guiding optimally convergent sequential pooled test selections. Computationally, however, Bayesian group testing poses considerable challenges as computational complexity grows exponentially with sample size. HPC and big data stacks are needed for assessing computational and statistical performance across fluctuating prevalence levels at large scales. Here, we study how to design and optimize critical computational components of Bayesian group testing, including lattice model representation, test selection algorithms, and statistical analysis schemes, under the context of parallel computing. To realize this, we propose a high-performance Bayesian group testing framework named HiBGT, based on Apache Spark, which systematically explores the design space of Bayesian group testing and provides comprehensive heuristics on how to achieve high-performance, highly scalable Bayesian group testing. We show that HiBGT can perform large-scale test selections (> 250 state iterations) and accelerate statistical analyzes up to 15.9x (up to 363x with little trade-offs) through a varied selection of sophisticated parallel computing techniques while achieving near linear scalability using up to 924 CPU cores. © 2022 IEEE.

An oil futures volatility forecast perspective on the selection of high-frequency jump tests

This paper examines the forecasting performances of high-frequency jump tests for oil futures volatility from a comprehensive perspective. It contributes to the literature by investigating which jump test is the best for oil futures volatility forecasting under different circumstances and whether the jump component extracted from multiple alternative tests is useful for further improving forecasting performance. Our results show that the jumps of the TOD test (Bollerslev et al., 2013) have satisfactory performance over the medium-term and especially the short-term forecasting horizons. Most importantly, the jump components from the intersection of multiple intraday tests further improve the forecasting performance. A variety of further discussions, including models controlling for stock market effects and considering periods of high (low) volatility and the COVID-19 pandemic period, confirm the conclusions. This paper attempts to shed light on oil futures volatility prediction from the perspective of jump test selection.

Considerations for the selection of tests for SARS-CoV-2 molecular diagnostics.

During the course of 2020, the outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spread rapidly across the world. Clinical diagnostic testing for SARS-Cov-2 infection has relied on the real-time Reverse Transcriptase Polymerase Chain Reaction and is considered the gold standard assay. Commercial vendors and laboratories quickly mobilised to develop diagnostic tests to detect the novel coronavirus, which was fundamentally important in the pandemic response. These SARS-Cov-2 assays were developed in line with the Food Drug Administration-Emergency Use Authorization guidance. Although new tests are continuously being developed, information about SARS-CoV-2 diagnostic molecular test accuracy has been limited and at times controversial. Therefore, the analytical and clinical performance of SARS-CoV-2 test kits should be carefully considered by the appropriate regulatory authorities and evaluated by independent laboratory validation. This would provide improved end-user confidence in selecting the most reliable and accurate diagnostic test. Moreover, it is unclear whether some of these rapidly developed tests have been subjected to rigorous quality control and assurance required under good manufacturing practice. Variable target gene regions selected for currently available tests, potential mutation in target gene regions, non-standardized pre-analytic phase, a lack of manufacturer independent validation data all create difficulties in selecting tests appropriate for different countries and laboratories. Here we provide information on test criteria which are important in the assessment and selection of SARS-CoV-2 molecular diagnostic tests and outline the potential issues associated with a proportion of the tests on the market.

Challenges in Regression Test Selection for End-to-End Testing of Microservice-based Software Systems

Dynamic regression test selection (RTS) techniques aim to minimize testing efforts by selecting tests using per-test execution traces. However, most existing RTS techniques are not applicable to microservice-based, or, more generally, distributed systems, as the dynamic program analysis is typically limited to a single system. In this paper, we describe our distributed RTS approach, microRTS, which targets automated and manual end-to-end testing in microservice-based software systems. We employ microRTS in a case study on a set of 20 manual end-to-end test cases across 12 versions of the German COVID-19 contact tracing application, a modern microservice-based software system. The results indicate that initially microRTS selects all manual test cases for each version. Yet, through semi-automated filtering of test traces, we are able to effectively reduce the testing effort by 10-50%. In contrast with prior results on automated unit tests, we find method-level granularity of per-test execution traces to be more suitable than class-level for manual end-to-end testing. CCS CONCEPTS • Software and its engineering ${\rightarrow}$ Software testing and debugging. © 2022 ACM.

A Rational Approach to Coagulation Testing.

Quality patient care requires the appropriate selection of laboratory tests. Irrelevant testing must be avoided, whereas pertinent testing is indispensable. The goals of this review are 3-fold: (1) to describe appropriate coagulation test selection for medical and surgical patients, (2) to describe appropriate coagulation testing specifically in individuals infected with SARS-CoV-2 causing COVID-19, and (3) to define the rational use of anticoagulant monitoring.